-
公开(公告)号：US20150232542A1
公开(公告)日：2015-08-20
申请号：US14592391
申请日：2015-01-08
申请人： Andreas WEIHOFEN , Jan Grimm , Roger Nitsch , Christoph Hock
发明人： Andreas WEIHOFEN , Jan Grimm , Roger Nitsch , Christoph Hock
IPC分类号： C07K16/18 , A61K49/16 , A61K45/06 , G01N33/68 , A61K39/395
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K49/16 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/92 , G01N33/6896 , G01N2333/4703 , G01N2800/2814 , G01N2800/2821 , G01N2800/2835
摘要： Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供的是人α-突触核蛋白特异性自身抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与α-突触核蛋白特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可以分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20110300077A1
公开(公告)日：2011-12-08
申请号：US13140699
申请日：2009-12-21
申请人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
发明人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
IPC分类号： A61K39/395 , C12P21/08 , C12N9/96 , C12N5/10 , C12N1/21 , A61K49/16 , G01N33/577 , C07K16/18 , A61P25/16 , A61P25/28 , A61P25/00 , A61K49/00 , C12N15/13 , C12N1/19
CPC分类号： C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供的是人α-突触核蛋白特异性自身抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与α-突触核蛋白特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可以分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20110182809A1
公开(公告)日：2011-07-28
申请号：US13003245
申请日：2009-07-09
申请人： Roger Nitsch , Olle Lindvall , Barbara Biscaro , Christine Ekdahl
发明人： Roger Nitsch , Olle Lindvall , Barbara Biscaro , Christine Ekdahl
IPC分类号： A61K51/10 , A61K39/395 , A61P25/28 , A61P25/00 , A61P25/16
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/74
摘要： The present description relates generally to methods of using Abeta binding molecules including, for example, antibodies and antibody fragments that recognize Abeta. The description provides methods of promoting neurogenesis, angiogenesis, synaptic activity and/or dendritic arborization using Abeta binding molecules. The description also provides methods of treating various diseases, disorder, injuries and conditions associated with amyloid plaques or the accumulation of Abeta.
摘要翻译： 本说明书一般涉及使用Abeta结合分子的方法，包括例如识别Abeta的抗体和抗体片段。 该描述提供了使用Abeta结合分子促进神经发生，血管生成，突触活性和/或树突状结构的方法。 该描述还提供了治疗与淀粉样蛋白斑块相关的各种疾病，障碍，损伤和病症或Abeta的积累的方法。
-
公开(公告)号：US20110020220A1
公开(公告)日：2011-01-27
申请号：US12677732
申请日：2008-09-15
IPC分类号： A61K51/00 , A61K49/00 , A61K39/395 , A61K35/12 , C12N5/00 , C12N15/63 , A61K31/7088 , C07K16/18 , C07H21/04
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622
摘要： The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
摘要翻译： 本发明公开了一种分离的抗体，其选择性地结合Abeta的C-末端部分并且是人源化的或完全人的。 本发明的抗体能够防止Aβ的低聚。 此外，诊断方法包括以下步骤：（i）标记抗体; （ii）向受试者鼻内或全身施用有效剂量的所述抗体; 并且（iii）公开了检测受试者体内部分标记的抗体的浓度和/或存在。
-
35.发明申请MEANS AND METHODS FOR ISOLATING AND DETERMINING NOVEL TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE, NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS AND COMPOSITIONS COMPRISING THE SAME 审中-公开用于分离和确定治疗神经损伤，神经病学或神经病学疾病的新目标的方法和方法及包含其的组合物公开(公告)号：US20100169988A1
公开(公告)日：2010-07-01
申请号：US12517420
申请日：2007-12-06
申请人： Bernhard Kohli , Uwe Konietzko , Roger Nitsch , Jan Grimm
发明人： Bernhard Kohli , Uwe Konietzko , Roger Nitsch , Jan Grimm
IPC分类号： G01N33/00 , A61K38/43 , A61K38/45 , A61K38/46 , C12Q1/68 , G01N33/53 , G01N33/573 , C12N9/12 , C12N9/14 , C12N9/90 , C12N5/00 , C40B40/06 , A61K38/16 , C07K14/00 , A01K67/00 , A61K38/52
CPC分类号： G01N33/6896 , A01K67/0275 , A01K2217/05 , A01K2217/206 , A01K2227/105 , A01K2267/0312 , A01K2267/0337 , C07K14/4711 , C07K2319/22 , C12N15/8509 , C12N2830/008
摘要： A novel method of identifying and obtaining molecules interacting with neurodegenerative, neurological or neuropsychiatric disorder-associated proteins is provided, which is suitable for drug screening and drug development. Furthermore, drugs and drug targets for the therapeutic intervention of neurodegenerative, neurological or neuropsychiatric disorders, in particular Alzheimer's disease are described.
摘要翻译： 提供了一种识别和获得与神经变性，神经系统或神经精神障碍相关蛋白相互作用的分子的新方法，其适用于药物筛选和药物开发。 此外，描述了用于神经变性，神经系统或神经精神障碍，特别是阿尔茨海默氏病的治疗性干预的药物和药物靶标。
-
36.发明申请Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining cyp46 genotype 审中-公开通过确定cyp46基因型识别阿尔茨海默病的遗传风险和评估治疗方法公开(公告)号：US20050048492A1
公开(公告)日：2005-03-03
申请号：US10495261
申请日：2002-03-01
IPC分类号： C12Q1/68 , G01N33/573 , G01N33/68 , G01N33/92
CPC分类号： G01N33/573 , G01N33/6896 , G01N33/92 , G01N2800/2821 , G01N2800/52
摘要： Based on the unexpected identification of a CYP46 gene polymorphism as a novel genetic risk factor that links cholesterol metabolism to Alzheimer's disease, the present invention provides a method of diagnosing or prognosticating Alzheimer's disease, or determining the propensity or predisposition of a subject to develop Alzheimer's disease. The method comprises detecting the presence or absence of a variation in the CYP46 gene which encodes the enzyme cholesterol 24-hydroxylase.
摘要翻译： 基于CYP46基因多态性的意外识别作为将胆固醇代谢与阿尔茨海默氏病联系起来的新型遗传风险因子，本发明提供了诊断或预测阿尔茨海默氏病或确定受试者发展为阿尔茨海默氏病的倾向或倾向的方法 。 该方法包括检测编码酶胆固醇24-羟化酶的CYP46基因的变异的存在或不存在。
-
公开(公告)号：US09273126B2
公开(公告)日：2016-03-01
申请号：US13667723
申请日：2012-11-02
IPC分类号： C07H21/04 , C07K16/18 , A61K39/395 , A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622
摘要： The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
摘要翻译： 本发明公开了一种分离的抗体，其选择性地结合Abeta的C-末端部分并且是人源化的或完全人的。 本发明的抗体能够防止Aβ的低聚。 此外，诊断方法包括以下步骤：（i）标记抗体; （ii）向受试者鼻内或全身施用有效剂量的所述抗体; 并且（iii）公开了检测受试者体内部分标记的抗体的浓度和/或存在。
-
公开(公告)号：US08940276B2
公开(公告)日：2015-01-27
申请号：US13140699
申请日：2009-12-21
申请人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
发明人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
IPC分类号： A61K39/395 , C12P21/08 , C12N9/96 , C07K16/18
CPC分类号： C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供的是人α-突触核蛋白特异性自身抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与α-突触核蛋白特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可以分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US08940272B2
公开(公告)日：2015-01-27
申请号：US13271118
申请日：2011-10-11
申请人： Roger Nitsch , Feng Chen , Jan Grimm , Jean-Luc Baeriswyl , Christoph Hock
发明人： Roger Nitsch , Feng Chen , Jan Grimm , Jean-Luc Baeriswyl , Christoph Hock
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , C07K14/47 , G01N33/68
CPC分类号： C07K16/18 , A61K39/3955 , A61K2039/505 , C07K14/47 , C07K14/4711 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/90 , C07K2317/92 , G01N33/6896 , G01N2333/47 , G01N2800/56
摘要： Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供新的人tau特异性抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与特异于tau的抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于tau靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20130295021A1
公开(公告)日：2013-11-07
申请号：US13878839
申请日：2011-10-11
申请人： Feng Chen , Jan Grimm , Jean-Luc Baeriswyl , Roger Nitsch , Christoph Hock
发明人： Feng Chen , Jan Grimm , Jean-Luc Baeriswyl , Roger Nitsch , Christoph Hock
IPC分类号： C07K16/18 , G01N33/68 , C07K14/47 , A61K39/395
CPC分类号： C07K16/18 , A61K39/3955 , A61K2039/505 , C07K14/47 , C07K14/4711 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/90 , C07K2317/92 , G01N33/6896 , G01N2333/47 , G01N2800/56
摘要： Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供人tau特异性抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与特异于tau的抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于tau靶向免疫治疗和诊断的药物和诊断组合物中。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.058 秒)
